Boomerang-shaped extended latissimus dorsi flap for combined breast reconstruction and body contouring following massive weight loss.

BMJ Case RepOct 5, 2026 (epub)
Case ReportPlastic Surgery

Rasmus Sørensen, Wahida Chakari, Jens Ahm Sørensen et al.

✦ AI-curated · Sources linked

Case in brief

A patient with a history of massive weight loss sought correction for her left-sided implant-based breast reconstruction, which had resulted in poor cosmetic outcomes and persistent pain. Due to prior abdominal surgery, an abdominal flap was not an option. Instead, a boomerang-shaped extended latissimus dorsi flap was utilized, successfully providing volume and contour to the breast while also addressing back aesthetics.

Diagnostic / clinical pearl

In cases of breast reconstruction after significant weight loss, consider alternative flap options like the latissimus dorsi flap when abdominal tissue is unavailable due to previous surgeries.

Source

PubMed · PMID 42833836

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.